The murine Leishmania major model has proven fertile ground for the elucidation of CD4+ T cell effector subset differentiation in vivo. The availability of a highly susceptible inbred strain, BALB/c, that develops progressive disease due to the aberrant differentiation of Th2, as opposed to protective Th1, responses, has allowed the identification of both T cell intrinsic as well as T cell extrinsic properties that combine to mediate disease outcome. The intrinsic T cell phenotype relates to the capacity of BALB/c-derived CD4+ T cells to acquire the potential to secrete IL-4 more readily than cells from other strains of mice. The extrinsic T cell phenotype relates to the creation of a T cell repertoire capable of recognizing the immunodominant parasite antigen. Together, the two traits confer the aberrant response seen in susceptible mice challenged with L. major.
Download full-text PDF |
Source |
---|
Exp Parasitol
January 2025
Grupo de Química Orgánica de Productos Naturales, Instituto de Química, Universidad de Antioquia-UdeA. Calle 70 # 52-21, Medellín, Colombia. Electronic address:
Cutaneous Leishmaniasis and Chagas disease are neglected tropical diseases that affect millions worldwide. Despite the high morbidity associated with these infections, current treatments are often highly toxic and are showing diminishing efficacy. Thus, new therapeutic options are urgently needed.
View Article and Find Full Text PDFBiomedicines
January 2025
Department of Biotechnology, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
Thiadiazine thione (THTT) has gained significant interest owing to its pharmacological potentials, particularly its antiparasitic and anti-inflammatory properties. Leishmaniasis is a clinical syndrome caused by infection with species and is associated with an inflammatory response and nociception. The available treatments against leishmaniasis are inadequate, as they are associated with high cost, toxicity, and increased resistance.
View Article and Find Full Text PDFMar Drugs
December 2024
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias (IUETSPC), Universidad de La Laguna (ULL), Avenida Astrofísico Francisco Sánchez s/n, 38206 La Laguna, Spain.
One of the most important steps in preclinical drug discovery is to demonstrate the in vivo efficacy of potential leishmanicidal compounds and good characteristics at the level of parasite killing prior to initiating human clinical trials. This paper describes the use of dehydrothyrsiferol (DT), isolated from the red alga , in a pharmaceutical form supported on Sepigel, and the in vivo efficacy against a mouse model of cutaneous leishmaniasis. Studying the ultrastructural effect of DT was also carried out to verify the suspected damage at the cellular level and determine the severity of damages produced in the homeostasis of promastigotes.
View Article and Find Full Text PDFParasit Vectors
January 2025
Laboratório de Imunologia Clínica, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, 21040-360, Brazil.
Background: Leishmaniases are neglected tropical diseases with great clinical and epidemiological importance. The current chemotherapy available for the treatment of leishmaniasis presents several problems, such as adverse effects, toxicity, long treatment time, and parasite resistance. The discovery of new therapeutic alternatives is extremely essential, and the discovery of cellular targets is a tool that helps in the development of new drugs.
View Article and Find Full Text PDFMicrob Pathog
January 2025
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!